Effects of vitamin E on a biomarker of inflammation and precursors of atherogenesis in chronic hemodialysis patients

Phillippine Journal of Internal Medicine

Volumn 49, Issue 4, 2011, Pages 206-215

  Coloma, Rachelle S ^a   Jocson, Vincent Rafael A ^a  

^a Veterans Memorial Medical Center   (Philippines)

Author keywords

Biomarker of inflammation; Chronic hemodialysis; Vitamin E

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA TOCOPHEROL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BICARBONATE; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM ANTAGONIST; CALCIUM CARBONATE; CHOLESTEROL; CLONAZEPAM; CLONIDINE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERROUS SULFATE; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISOSORBIDE MONONITRATE; LORATADINE; LOW DENSITY LIPOPROTEIN; PLACEBO; PROTON PUMP INHIBITOR; SEVELAMER; TERAZOSIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84857287961     PISSN: 01199641     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association Of Morbidity With Markers of Nutrition and Inflammation In Chronic Hemodialysis Patients. Kidney International 55: 19451951, 1999.
2. Saran R, Noval JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R, Handelman GJ, Barbato D, Weitzel W, D'Alecy LG, Rajagopalan S. Impact of vitamin E on Plasma Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease (CKD): A Pilot Study. Nephrology Dialysis Transplantation 18: 2415-2420, 2003.
3. Pecoits-Filho R, Lindhold B, Stenvinkel P. The Malnutrition, Inflammation, and Atherosclerosis (MIA) Syndrome-Heart of the Matter. Nephrology Dialysis Transplantation 17:28-31, 2002.
4. Tonelli M, Sacks F, Pfeffer M, Jhanghari GS, Curhan G. Biomarkers of Inflammation and Progression of Chronic Kidney Disease. Kidney International 68: 237-245, 2005.
5. Nhuyen-Khoa T, Massy Z, De Bandt J, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke T, Lacour B, Thevenin M. Oxidative Stress and Hemodialysis: Role of Inflammation and Duration of Dialysis Treatment. Nephrology Dialysis Transplantation 16: 335-340, 2001.
6. Locatelli F, Canaud B, Eckardt K, Stenvinkel P, Wanner C, Zoccali C. Oxidative Stress in End-Stage Renal Disease; An Emerging Threat to Patient Outcome. Nephrology Dialysis Transplantation 18:1272-1280, 2003.
7. Ramos LF, Shintani A, Ikizler TA, Himmelfarb J. Oxidative Stress and Inflammation are Associated with Adiposity in Moderate to Severe CKD. Journal of the American Society of Nephrology 19:593-599, 2008.
8. Drueke TB, Nguyen-Khoa T, Massy Z, Witko-Sarsat V, Lacour B, Descamps-Latcha B. Role of Oxidixed Low-Density Lipoprotein in the Atherosclerosis of Uremia. Kidney International 59: S114-S119, 2001.
9. Engler MM, Engler MB, Malloy M, Chiu EY, Schloetter MC, Paul SM, Stuehlinger M, Lin KY, Cooke JP, Morrow JD, Ridker PM, Rifai N, Miller E, Witztum JL, Mietus-Snyder M. Antioxidant Vitamin C and E Improve Endothelial Function in Children with Hyperlipidemia. Circulation 108:1059-1063, 2003.
10. Esterbauer H, Dieber-Rotheneder M, Striegl G, Waeg G. Role of vitamin E in Preventing the Oxidation of Low-Density Lipoprotein. American Journal of Clinical Nutrition 53:314S-321S, 1991.
11. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Laina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green M. Secondary Prevention with Antioxidants of Cardiovascular Disease in End-Stage Renal Disease (SPACE): Randomized Placebo Controlled Trial. The Lancet 356: 1213-1218, 2000.
12. Jialal I, Fuller CJ, Huet BA. The Effect of α-Tocopherol Supplementation on LDL Oxidation. Arteriosclerosis, Thrombosis, and Vascular Biology 15: 190-198, 1995.
13. Saldeen T, Li D, Mehta JL. Differential Effects of Alpha-and Gamma-Tocopherol on Low-Density Lipoprotein Oxidation, Superoxide Activity, Platelet Aggregation and Arterial Thrombogenesis. Journal of American College of Cardiology 34: 1208-1215, 1999.
14. Kirmizis D, Chatzidimitriou D. Antiatherogenic Effects of vitamin E: The Search for the Holy Grail. Vascular Health and Risk Management 5: 767-774, 2009.
15. Stenvinkel P. Inflammation in End-Stage Renal Failure: Could It Be Treated? Nephrology Dialysis Transplantation 17(Suppl 8): 33-38, 2002.
16. Deschamps-Latcha B, Goldfarb B, Nguyen AT. Establishing the Relationship Between Complement Activation and Stimulation of Phagocyte Oxidative Metabolism in Hemodialyzed Patients: A Randomized Prospective Study. Nephron 59: 279-286, 1991.
17. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wnnaer C. Inflammation Enhances Cardiovascular Risk and Mortality in Hemodialysis Patients. Kidney International 55: 648-658, 1999
18. Yeun JY, Levine RA, Mantadilok V, Kyasen GA. C-reactive Protein Predicts All-Cause and Cardiovascular Mortality in Hemodialysis Patients. American Journal of Kidney Diseases 35: 469-476, 2000.
19. Zoccali C, Benedicto FA, Mallamaci F. Inflammation is Associated with Carotid Atherosclerosis in Dialysis Patients. Journal of Hypertension 18: 1207-1213, 2000.
20. Mafra D, Santos FR, Lobo JC, de Mattos Grosso D, Barreira AL, Velarde LGC, Abdalla DSP, Leite M. Alpha-Tocopherol Supplementation Decreases Electronegative Low-Density Lipoprotein Concentration [LDL(-)] in Haemodialysis Patients. Nephrology Dialysis Transplantation 24: 1587-1592, 2009.
21. Ziouzenkova O, Asatryan L, Akmal M. Oxidative Cross-Linking of Apo-B100 and Hemoglobin Results in Low-Density Lipoprotein Modification in Blood Relevance to Atherogenesis Caused by Hemodialysis. Journal of Biological Chemistry 274: 18916-19924, 1999.
22. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H. Effect of Oral Supplementation with D-α-Tocopherol on the vitamin E Content of Human Low Density Lipoproteins and Resistance to Oxidation. Journal of Lipid Research 32: 1325-1332, 1991.
23. Jürgens G, Hoff HF, Chisolm GM III, Esterbauer H. Modification of Human Serum Low Density Lipoprotein by Oxidation: Characterization and Pathophysiological Implications. Chem Phys Lipids 45:315-336, 1987.
24. Witztum JL, Steinberg D. Role of Oxidized Low Density Lipoprotein in Atherogenesis. J Clin Invest. 88:1785-1792, 1991.
25. Henricksen T, Mahoney TM, Steinberg D. Enhanced Macrophage Degradation of Biologically Modified Low-Density Lipoprotein. Arteriosclerosis. 3:149-159, 1983.
26. Morel DW, Hessler JR, Chisolm GM. Low Density Lipoprotein Cytotoxicity Induced by Free Radical Peroxidation of Lipid. J Lipid Res. 24:1070-1076, 1983.
27. Quinn MT, Parthasarathy S, Steinberg D. Endothelial Cell-Derived Chemotactic Activity for Mouse Peritoneal Macrophages and the Effects of Modified Forms of Low Density Lipoprotein. Proc Natl Acad Sci U S A. 82:5949-5953, 1985.
28. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively-Modified Low Density Lipoproteins: A Potential Role in Recruitment and Retention of Monocyte/Macrophages During Atherogenesis. Proc Natl Acad Sci U S A.84:2995-2998, 1987.
29. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally-Modified Low Density Lipoprotein Stimulates Monocyte-Endothelial Interactions. J Clin Invest. 85:1260-1266, 1990.
30. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente JA, Berliner JA, Drinkwater DC, Laks H, Fogelman AM. Monocyte Transmigration Induced by Modification of Low Density Lipoprotein in Cocultures of Human Aortic Wall Cells is Due to Induction of Monocyte Chemotactic Protein 1 Synthesis and is Abolished by High Density Lipoprotein. J Clin Invest. 88:2039-2046, 1991.
31. Thomas CE, Jackson RL, Ohlweiler DF, Ku G. Multiple Lipid Oxidation Products in Low Density Lipoproteins Induce Interleukin-1 Beta Release from Human Blood Mononuclear Cells. J Lipid Res. 35:417-427, 1994.
32. Drake TA, Hannani K, Fei H, Lavi S, Berliner JA. Minimally Oxidized Low-Density Lipoprotein Induces Tissue Factor Expression in Cultured Human Endothelial Cells. Am J Pathol.138:601-607, 1991
33. Galli F, Varga Z, Balla J, Ferraro B, Canestrari F, Floridi A, Kakuk G, Buonchristiani U. vitamin E, Lipid Profile and Peroxidation in Hemodialysis Patients. Kidney International 59 (Suppl 78): S-148-154, 2001.
34. Ilam KN, O'Byrne D, Devaraj S. Alpha-Tocpherol Supplementation Decreases the Oxidative Susceptibility of LDL in Renal Failure Patients on Dialysis Therapy. Atherosclerosis 150:217-224, 2000.
35. Wanner C, Quaschning T. Dyslipidemia and Renal Disease: Pathogenesis and Clinical Consequences. Current Opinion in Nephrology and Hypertension 10:195-201, 2001.
36. Kalantar-Zadeh K, Kilpatrick RD, Kopple JD, Stringer WW. A Matched Comparison of Serum Lipids Between Hemodialysis Patients and Nondialysis Morbid Controls. Hemodialysis International 9:314-324, 2005.
37. Krauss RM. Hold the Antioxidants and Improve Plasma Lipids? J. Clin. Invest. 113:1253-1255, 2004.
38. Heart Protection Study Collaborative Group: MRC/ BHF Heart Protection Study of Antioxidant Vitamin Supplementation in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Lancet.360:23-33, 2002.
39. Lu L, Erhard P, Salomon RG, Weiss MF. Serum vitamin E and Oxidative Protein Modification in Hemodialysis: A Randomized Clinical Trial. American Journal of Kidney Diseases 50: 305-313, 2007.